- Home
- VIGL vs KNDI Comparison
VIGL vs KNDI Comparison
Compare VIGL & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- KNDI
- Stock Information
- Founded
- VIGL 2020
- KNDI 2002
- Country
- VIGL United States
- KNDI China
- Employees
- VIGL N/A
- KNDI N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- KNDI Auto Manufacturing
- Sector
- VIGL Health Care
- KNDI Consumer Discretionary
- Exchange
- VIGL Nasdaq
- KNDI Nasdaq
- Market Cap
- VIGL 89.3M
- KNDI 142.0M
- IPO Year
- VIGL 2022
- KNDI N/A
- Fundamental
- Price
- VIGL $2.09
- KNDI $1.44
- Analyst Decision
- VIGL Strong Buy
- KNDI
- Analyst Count
- VIGL 5
- KNDI 0
- Target Price
- VIGL $21.00
- KNDI N/A
- AVG Volume (30 Days)
- VIGL 287.9K
- KNDI 323.9K
- Earning Date
- VIGL 05-06-2025
- KNDI 03-25-2025
- Dividend Yield
- VIGL N/A
- KNDI N/A
- EPS Growth
- VIGL N/A
- KNDI N/A
- EPS
- VIGL N/A
- KNDI N/A
- Revenue
- VIGL N/A
- KNDI $118,127,232.00
- Revenue This Year
- VIGL N/A
- KNDI N/A
- Revenue Next Year
- VIGL N/A
- KNDI N/A
- P/E Ratio
- VIGL N/A
- KNDI N/A
- Revenue Growth
- VIGL N/A
- KNDI N/A
- 52 Week Low
- VIGL $1.49
- KNDI $0.89
- 52 Week High
- VIGL $6.06
- KNDI $2.98
- Technical
- Relative Strength Index (RSI)
- VIGL 45.86
- KNDI 53.97
- Support Level
- VIGL $2.15
- KNDI $1.27
- Resistance Level
- VIGL $2.55
- KNDI $1.73
- Average True Range (ATR)
- VIGL 0.22
- KNDI 0.17
- MACD
- VIGL -0.04
- KNDI -0.00
- Stochastic Oscillator
- VIGL 20.59
- KNDI 35.19
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in the development, production, and distribution of electric vehicle (EV) products, EV parts, and off-road vehicle products in the Chinese market. Other product offerings include all-terrain vehicles, go-karts, utility vehicles, battery packs, and other systems. It generates maximum revenue through off-road vehicles. The company generates the majority of its revenue from the United states along with other Countries, followed by China.